One hundred thirteen adults and children with hemophilia or other congenital bleeding disorders were vaccinated against the hepatitis B virus. Each patient was given 3 subcutaneous injections of the vaccine at monthly intervals and then a 4th booster dose 14 months after the first. The vaccine was highly immunogenic, since 111 of 113 patients (98%) produced anti-HBs (10 mIU/ml or more). After the first 3 vaccine doses and after the booster dose, 10 anti-LAV/HTLV-III-positive hemophiliacs produced anti-HBs but had a lower average titer than anti-LAV/HTLV-III-negative hemophiliacs. Of the 23 patients treated with concentrates in the 15-month postvaccination period only, none acquired HBV infection. Of the 50 patients treated with concentrates also in the 6-month prevaccination period, one developed hepatitis B. In summary, the vaccine was highly immunogenic in both children and adults with hemophilia; anti-LAV/HTLV-III-positive patients responded to the vaccine, but the average anti-HBs response was lower; no case of hepatitis B occurred in patients treated with concentrates only in the postvaccination period.
Hepatitis B vaccination of 113 hemophiliacs: lower antibody response in anti-LAV/HTLV-III-positive patients / A.R. ZANETTI, P.M. MANNUCCI, E. TANZI, G.A. MORONI, M. DE PASCHALE, M. MORFINI, V. CARNELLI, M.C. TIRINDELLI, R. DE BIASI, N. CIAVARELLA, V. DE ROSA, F. RODEGHIERO, M. COLOMBO. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 23:4(1986), pp. 339-345. [10.1002/ajh.2830230406]
Hepatitis B vaccination of 113 hemophiliacs: lower antibody response in anti-LAV/HTLV-III-positive patients
A.R. ZANETTIPrimo
;P.M. MANNUCCISecondo
;E. TANZI;V. CARNELLI;M. COLOMBOUltimo
1986
Abstract
One hundred thirteen adults and children with hemophilia or other congenital bleeding disorders were vaccinated against the hepatitis B virus. Each patient was given 3 subcutaneous injections of the vaccine at monthly intervals and then a 4th booster dose 14 months after the first. The vaccine was highly immunogenic, since 111 of 113 patients (98%) produced anti-HBs (10 mIU/ml or more). After the first 3 vaccine doses and after the booster dose, 10 anti-LAV/HTLV-III-positive hemophiliacs produced anti-HBs but had a lower average titer than anti-LAV/HTLV-III-negative hemophiliacs. Of the 23 patients treated with concentrates in the 15-month postvaccination period only, none acquired HBV infection. Of the 50 patients treated with concentrates also in the 6-month prevaccination period, one developed hepatitis B. In summary, the vaccine was highly immunogenic in both children and adults with hemophilia; anti-LAV/HTLV-III-positive patients responded to the vaccine, but the average anti-HBs response was lower; no case of hepatitis B occurred in patients treated with concentrates only in the postvaccination period.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.